Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1969 1
1971 3
1973 2
1974 4
1975 9
1976 17
1977 25
1978 20
1979 40
1980 41
1981 35
1982 37
1983 24
1984 34
1985 26
1986 49
1987 49
1988 35
1989 55
1990 59
1991 75
1992 72
1993 103
1994 99
1995 106
1996 112
1997 99
1998 97
1999 126
2000 147
2001 157
2002 157
2003 155
2004 203
2005 221
2006 247
2007 272
2008 282
2009 317
2010 323
2011 403
2012 452
2013 499
2014 517
2015 629
2016 567
2017 553
2018 563
2019 623
2020 707
2021 758
2022 737
2023 687
2024 274

Text availability

Article attribute

Article type

Publication date

Search Results

10,500 results

Results by year

Filters applied: . Clear all
Page 1
Endometrial cancer.
Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Amant F, et al. Lancet. 2005 Aug 6-12;366(9484):491-505. doi: 10.1016/S0140-6736(05)67063-8. Lancet. 2005. PMID: 16084259 Free article. Review.
Each year, endometrial cancer develops in about 142,000 women worldwide, and an estimated 42,000 women die from this cancer. The typical age-incidence curve for endometrial cancer shows that most cases are diagnosed after the menopause, with the highes …
Each year, endometrial cancer develops in about 142,000 women worldwide, and an estimated 42,000 women die from this cancer. T …
Diagnosis and Management of Endometrial Cancer.
Braun MM, Overbeek-Wager EA, Grumbo RJ. Braun MM, et al. Am Fam Physician. 2016 Mar 15;93(6):468-74. Am Fam Physician. 2016. PMID: 26977831 Free article. Review.
Endometrial cancer is the most common gynecologic malignancy. It is the fourth most common cancer in women in the United States after breast, lung, and colorectal cancers. ...Controlling risk factors such as obesity, diabetes, and hypertension could play a role in t …
Endometrial cancer is the most common gynecologic malignancy. It is the fourth most common cancer in women in the United State …
Dietary Factors and Endometrial Cancer Risk: A Mendelian Randomization Study.
Wang X, Glubb DM, O'Mara TA. Wang X, et al. Nutrients. 2023 Jan 24;15(3):603. doi: 10.3390/nu15030603. Nutrients. 2023. PMID: 36771310 Free PMC article.
Given the strong association between obesity and endometrial cancer risk, dietary factors may play an important role in the development of this cancer. ...Genetically predicted vitamin C levels were found to be strongly associated with endometrial cancer …
Given the strong association between obesity and endometrial cancer risk, dietary factors may play an important role in the de …
Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy.
van den Heerik ASVM, Horeweg N, de Boer SM, Bosse T, Creutzberg CL. van den Heerik ASVM, et al. Int J Gynecol Cancer. 2021 Apr;31(4):594-604. doi: 10.1136/ijgc-2020-001822. Epub 2020 Oct 20. Int J Gynecol Cancer. 2021. PMID: 33082238 Free PMC article. Review.
Endometrial cancer is primarily treated with surgery. Adjuvant treatment strategies for endometrial cancer, such as external beam pelvic radiotherapy, vaginal brachytherapy, chemotherapy, and combined chemotherapy and radiotherapy, have been studied in …
Endometrial cancer is primarily treated with surgery. Adjuvant treatment strategies for endometrial cancer, such …
Endometrial Cancer MRI staging: Updated Guidelines of the European Society of Urogenital Radiology.
Nougaret S, Horta M, Sala E, Lakhman Y, Thomassin-Naggara I, Kido A, Masselli G, Bharwani N, Sadowski E, Ertmer A, Otero-Garcia M, Kubik-Huch RA, Cunha TM, Rockall A, Forstner R. Nougaret S, et al. Eur Radiol. 2019 Feb;29(2):792-805. doi: 10.1007/s00330-018-5515-y. Epub 2018 Jul 11. Eur Radiol. 2019. PMID: 29995239 Review.
OBJECTIVES: To update the 2009 ESUR endometrial cancer guidelines and propose strategies to standardize image acquisition, interpretation and reporting for endometrial cancer staging with MRI. ...CONCLUSIONS: These consensus recommendations should be u …
OBJECTIVES: To update the 2009 ESUR endometrial cancer guidelines and propose strategies to standardize image acquisition, int …
Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations.
Hamilton CA, Pothuri B, Arend RC, Backes FJ, Gehrig PA, Soliman PT, Thompson JS, Urban RR, Burke WM. Hamilton CA, et al. Gynecol Oncol. 2021 Mar;160(3):817-826. doi: 10.1016/j.ygyno.2020.12.021. Epub 2021 Jan 27. Gynecol Oncol. 2021. PMID: 33516529 Review.
INTRODUCTION: In 2014, the Society of Gynecologic Oncology's Clinical Practice Committee published a clinical update reviewing the treatment of women with endometrial cancer. At that time, there had been significant advances in the diagnosis, work-up, surgical manag …
INTRODUCTION: In 2014, the Society of Gynecologic Oncology's Clinical Practice Committee published a clinical update reviewing the treatment …
Conservative treatment in early stage endometrial cancer: a review.
Trojano G, Olivieri C, Tinelli R, Damiani GR, Pellegrino A, Cicinelli E. Trojano G, et al. Acta Biomed. 2019 Dec 23;90(4):405-410. doi: 10.23750/abm.v90i4.7800. Acta Biomed. 2019. PMID: 31910163 Free PMC article. Review.
Endometrial Cancer (EC) is the commonest gynecological cancer and its incidence is increasing. ...We reviewed the published literature to clarify in fertile women who have not yet fulfilled their desire for motherhood, what are the strategies, the risks of a conserv …
Endometrial Cancer (EC) is the commonest gynecological cancer and its incidence is increasing. ...We reviewed the published li …
p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification.
Jamieson A, Thompson EF, Huvila J, Gilks CB, McAlpine JN. Jamieson A, et al. Int J Gynecol Cancer. 2021 Jun;31(6):907-913. doi: 10.1136/ijgc-2020-002256. Epub 2021 Feb 15. Int J Gynecol Cancer. 2021. PMID: 33589443 Review.
Immunostaining for p53 stratifies the remaining endometrial cancers into those with wild-type staining pattern and those with mutant pattern staining (p53abn endometrial cancer). This latter group of p53abn endometrial cancer is the subject of this rev …
Immunostaining for p53 stratifies the remaining endometrial cancers into those with wild-type staining pattern and those with mutant pattern …
Treatment options for molecular subtypes of endometrial cancer in 2023.
Karpel HC, Slomovitz B, Coleman RL, Pothuri B. Karpel HC, et al. Curr Opin Obstet Gynecol. 2023 Jun 1;35(3):270-278. doi: 10.1097/GCO.0000000000000855. Epub 2023 Mar 20. Curr Opin Obstet Gynecol. 2023. PMID: 36943683 Review.
Trastuzumab is NCCN compendium listed for HER2-positive serous endometrial cancer, which are primarily p53-abnormal. Antibody-drug conjugates targeting low and high HER2 levels show promise in breast cancer, and are beginning to be studied in endometrial c …
Trastuzumab is NCCN compendium listed for HER2-positive serous endometrial cancer, which are primarily p53-abnormal. Antibody- …
Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts.
Fremond S, Andani S, Barkey Wolf J, Dijkstra J, Melsbach S, Jobsen JJ, Brinkhuis M, Roothaan S, Jurgenliemk-Schulz I, Lutgens LCHW, Nout RA, van der Steen-Banasik EM, de Boer SM, Powell ME, Singh N, Mileshkin LR, Mackay HJ, Leary A, Nijman HW, Smit VTHBM, Creutzberg CL, Horeweg N, Koelzer VH, Bosse T. Fremond S, et al. Lancet Digit Health. 2023 Feb;5(2):e71-e82. doi: 10.1016/S2589-7500(22)00210-2. Epub 2022 Dec 7. Lancet Digit Health. 2023. PMID: 36496303 Free article. Clinical Trial.
The ten patients with aggressive p53abn endometrial cancer that was predicted as MMRd showed inflammatory morphology and appeared to have a better prognosis than patients with correctly predicted p53abn endometrial cancer (p=0.30). ...Patients with MMR …
The ten patients with aggressive p53abn endometrial cancer that was predicted as MMRd showed inflammatory morphology and appea …
10,500 results
You have reached the last available page of results. Please see the User Guide for more information.